What is NDC 50242-145?

50242-145 is the product NDC for Perjeta (pertuzumab), Pertuzumab 30 mg/mL injection, solution, concentrate, listed with the FDA by Genentech, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.

Genentech, Inc., NDC labeler code 50242. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Perjeta?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Perjeta NDC 50242-145 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)50242-145Labeler and product segments. Claims need a package NDC.

Product NDC at billing width50242-0145Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
50242-145-01	50242014501	1 VIAL, SINGLE-USE in 1 CARTON (50242-145-01) / 14 mL in 1 VIAL, SINGLE-USEMarketed from Jun 8, 2012

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Perjeta
Generic name (nonproprietary): pertuzumab
Active ingredients: Pertuzumab — 30 mg/mL
Dosage form: Injection, Solution, Concentrate
Route: Intravenous
Labeler: Genentech, Inc.NDC labeler code 50242
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 125409
Marketing start: Jun 8, 2012
Listing expires: Dec 31, 2027
Other FDA classes: HER2/Neu/cerbB2 Antagonists (Mechanism)
Identifiers: Product ID 50242-145_dfebfe9c-a0c5-41d8-bf11-ed643627e264SPL ID dfebfe9c-a0c5-41d8-bf11-ed643627e264SPL set ID 17f85d17-ab71-4f5b-9fe3-0b8c822f69ffRxCUI 1298948, 1298953UNII K16AIQ8CTM
Pharmacologic class: HER2/neu Receptor Antagonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N450242014501 followed by a unit qualifier and the quantity

Package 50242-0145-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Apr 30, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

PERJETA is a HER2/neu receptor antagonist indicated for: Use in combination with trastuzumab and docetaxel for treatment of adults with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. ( 1.1 ) Use in combination with trastuzumab and chemotherapy as neoadjuvant treatment of adults with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. ( 1.2 , 2.2 , 14.2 ) adjuvant treatment of adults with HER2-positive early breast cancer at high risk of recurrence ( 1.2 , 2.2 , 14.3 …

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 50242-145

What is NDC 50242-145?: 50242-145 is the product NDC for Perjeta (pertuzumab), Pertuzumab 30 mg/mL injection, solution, concentrate, listed with the FDA by Genentech, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Perjeta (Pertuzumab).
What is the active ingredient?: Pertuzumab.
Who is the labeler?: Genentech, Inc., NDC labeler code 50242. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Perjeta?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Perjeta (Pertuzumab) NDC 50242-145